-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The ENCHANTED study is a multicenter, large-scale randomized controlled clinical trial based on patients with acute ischemic stroke (AIS) intravenous thrombolysis
.
This study aims to determine the effectiveness and safety of low- and standard-dose intravenous alteplase in patients with AIS, as well as the enhancement and guidelines recommended in lowering blood pressure in patients with AIS
.
In order to explore the impact of low-dose alteplase intravenous administration and intensive blood pressure lowering on the outcome of AIS patients, the team of Professor Craig Anderson from the George Institute of Global Health at the University of New South Wales in Australia conducted this study.
The results of the study will be published in 2021.
It was announced as an electronic poster at the Stroke Conference (WSC 2021)
.
Author of this article: Yimaitong WSC report team compiled and compiled, please do not reprint without authorization
.
Research Introduction The researchers explored the effects of low-dose alteplase intravenous administration and intensive blood pressure lowering on the outcome of AIS patients based on the vascular obstruction status/location of ENCHANTED subjects
.
In patients undergoing CT or MRI angiography at baseline, the researchers grouped the degree of vascular occlusion according to none (NVO), medium (MVO), or large (LVO), and used the Logistic regression model to determine the vascular occlusion status/location for 90 days Outcome (modified Rankin Scale [mRS] changes, other mRS cut scores, intracranial hemorrhage, early neurological deterioration and recanalization)
.
Main findings: ➤A total of 940 participants: 607 were in the alteplase group, 243 were in the blood pressure group, and the remaining 90 were assigned to two groups
.
Compared with the NVO group, the LVO group had a worse functional outcome (mRS change, adjusted OR[95%CI]2.
13[1.
56-2.
90]), but comparable in the MVO group (1.
34[0.
96-1.
88])
.
➤There was no difference in the correlation between the dose of alteplase and the intensity of blood pressure reduction and the outcome between the NVO/MVO/LVO groups
.
Conclusion According to ENCHANTED's analysis, the functional outcome of alteplase dose or antihypertensive intensity is not affected by the vascular obstruction status/location, although these results are affected by low statistical power
.
Yimaitong compiled from: THROMBOLYSIS OUTCOMES ACCORDING TO ARTERIAL CHARACTERISTICS OF ACUTE ISCHEMIC STROKE BY ALTEPLASE DOSE AND BLOOD PRESSURE TARGET.
WSC 2021.
.
This study aims to determine the effectiveness and safety of low- and standard-dose intravenous alteplase in patients with AIS, as well as the enhancement and guidelines recommended in lowering blood pressure in patients with AIS
.
In order to explore the impact of low-dose alteplase intravenous administration and intensive blood pressure lowering on the outcome of AIS patients, the team of Professor Craig Anderson from the George Institute of Global Health at the University of New South Wales in Australia conducted this study.
The results of the study will be published in 2021.
It was announced as an electronic poster at the Stroke Conference (WSC 2021)
.
Author of this article: Yimaitong WSC report team compiled and compiled, please do not reprint without authorization
.
Research Introduction The researchers explored the effects of low-dose alteplase intravenous administration and intensive blood pressure lowering on the outcome of AIS patients based on the vascular obstruction status/location of ENCHANTED subjects
.
In patients undergoing CT or MRI angiography at baseline, the researchers grouped the degree of vascular occlusion according to none (NVO), medium (MVO), or large (LVO), and used the Logistic regression model to determine the vascular occlusion status/location for 90 days Outcome (modified Rankin Scale [mRS] changes, other mRS cut scores, intracranial hemorrhage, early neurological deterioration and recanalization)
.
Main findings: ➤A total of 940 participants: 607 were in the alteplase group, 243 were in the blood pressure group, and the remaining 90 were assigned to two groups
.
Compared with the NVO group, the LVO group had a worse functional outcome (mRS change, adjusted OR[95%CI]2.
13[1.
56-2.
90]), but comparable in the MVO group (1.
34[0.
96-1.
88])
.
➤There was no difference in the correlation between the dose of alteplase and the intensity of blood pressure reduction and the outcome between the NVO/MVO/LVO groups
.
Conclusion According to ENCHANTED's analysis, the functional outcome of alteplase dose or antihypertensive intensity is not affected by the vascular obstruction status/location, although these results are affected by low statistical power
.
Yimaitong compiled from: THROMBOLYSIS OUTCOMES ACCORDING TO ARTERIAL CHARACTERISTICS OF ACUTE ISCHEMIC STROKE BY ALTEPLASE DOSE AND BLOOD PRESSURE TARGET.
WSC 2021.
